Meridian Bioscience (VIVO) Aktsia Kursus

Meridian Bioscience Kursus

NASDAQ·SULETUD
2,27
​
Turg suletud

Viimase 19 aasta jooksul kasvas Meridian Bioscience käive 8,9 % aastas ja jõudis 333,02 M USD-ni. Kasum aktsia kohta kasvas 8,4 % aastas viimase 19 aasta jooksul. Meridian Bioscience netomarginaal 12,7 % on tõusnud võrreldes 11,1 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 5,51 %. Väljamaksesuhe on umbes 22 % kasumist.

Meridian Bioscience aktsiahinnad

Hangi need andmed Eulerpool API kaudu

100 000 päringut/kuus tasuta · krediitkaarti pole

Meridian Bioscience ärimudel ja aktsia analüüs

Meridian Bioscience Inc. on globaalne ettevõte, mis on spetsialiseerunud nakkushaiguste ja muude meditsiiniliste seisundite diagnoosimiseks mõeldud testkomplektide arendamisele, tootmisele ja levitamisele. Ettevõtte asutas 1976. aastal William J. Motto ning selle algne fookus oli ensüümimmunoanalüütide (EIA) arendamisel. Aastate jooksul on ettevõte kasvanud ja laiendanud oma tootevalikut, saades juhtivaks akute ja krooniliste haigusseisundite, nakkushaiguste, seedetrakti infektsioonide ning viroloogia valdkonna diagnostiliste testikomplektide tarnijaks. Ettevõtte edu põhjuseks on selle mitmekesine testikomplektide valik erinevates meditsiinivaldkondades, sealhulgas immunoloogia, nakkushaigused, sugulisel teel levivad haigused, gastroenteroloogia ja viroloogia. Lisaks hoiab Meridian Bioscience Inc. end kursis biotehnoloogia viimaste tehnoloogiliste uuendustega, tagades seeläbi oma testide kiire ja tõhusa toimimise. Ettevõte tegutseb globaalselt, koostööd tehes ülikoolide, uurimusasutuste, riigiagentuuride ja jaemüüjatega, et tagada oma toodete maailmalaululine levitamine ja turustamine. Kokkuvõttes on Meridian Bioscience Inc. innovaatiline ettevõte, mis on spetsialiseerunud nakkushaiguste ja muude meditsiiniliste seisundite diagnoosimiseks mõeldud testikomplektide arendamisele, tootmisele ja levitamisele. Lai tootevalik, mis hõlmab immunoloogiatooteid, nakkushaiguste diagnostikat, sugulisel teel levivate haiguste testikomplekte, gastroenteroloogiat, viroloogiat ja molekulaardiagnostikat, koos täpsete tehnoloogiatega pakub kiiret, täpset ja usaldusväärset diagnostilist tuge.

Korduma kippuvad küsimused Meridian Bioscience aktsia kohta

The business model of Meridian Bioscience Inc revolves around manufacturing and distributing diagnostic products for the healthcare industry. With a focus on infectious disease testing, the company provides a range of products including molecular and immunoassay tests, as well as reagents and related equipment. Meridian Bioscience Inc aims to develop innovative solutions for quick and accurate diagnosis, helping healthcare professionals worldwide make informed decisions. Through its expertise and continual investment in research and development, the company strives to improve patient outcomes and contribute to the overall public health. Meridian Bioscience Inc's commitment to quality and customer satisfaction is evident in their comprehensive portfolio of diagnostic solutions.

Meridian Bioscience Inc is primarily active in the healthcare and life sciences industries.

The main competitors of Meridian Bioscience Inc in the market are companies like Thermo Fisher Scientific, BD (Becton, Dickinson and Company), Quidel Corporation, and Bio-Rad Laboratories. These companies operate in the healthcare and diagnostics industry, offering similar products and services. Meridian Bioscience Inc competes based on factors such as product quality, technological advancements, pricing strategy, and customer satisfaction. While Thermo Fisher Scientific is a well-established player in the market, Meridian Bioscience Inc continues to carve its niche through innovative solutions and a strong customer-centric approach.

Meridian Bioscience Inc is a leading life science company that develops and markets a broad range of innovative diagnostic products. Founded in 1976, the company has a rich history and a strong background in developing and commercializing diagnostic tests for various infectious diseases. Meridian Bioscience Inc has evolved over the years and has expanded its product portfolio to cater to the needs of laboratories, hospitals, and other healthcare providers worldwide. With a focus on quality, accuracy, and reliability, the company has garnered a reputation for delivering efficient and effective diagnostic solutions. Meridian Bioscience Inc remains committed to advancing healthcare and improving patient outcomes through its cutting-edge diagnostic technologies and dedication to innovation.

Meridian Bioscience Inc has achieved several significant milestones throughout its history. One notable accomplishment is the company's development and commercialization of innovative diagnostic test kits for various diseases and healthcare conditions. Furthermore, Meridian Bioscience Inc has consistently expanded its product portfolio, introducing novel technologies to improve healthcare outcomes. The company's dedication to research and development has led to the successful launch of multiple FDA-cleared and CE-marked diagnostic tests. Meridian Bioscience Inc's commitment to quality has enabled it to establish a strong presence in the global diagnostics market.

Meridian Bioscience Inc is primarily present in the United States.

Meridian Bioscience Inc represents a strong set of values and corporate philosophy. The company is committed to quality and innovation in the field of biotechnology. They strive to provide accurate and reliable diagnostic solutions to improve patient care. Meridian Bioscience Inc also prioritizes integrity and ethical conduct in all aspects of their business operations. With a focus on customer satisfaction, they aim to exceed expectations and deliver exceptional products and services. As an industry leader, Meridian Bioscience Inc continues to drive advancements in the healthcare sector through their dedication to excellence and integrity.

7 analüütikut hindavad praegu Meridian Bioscience aktsiat: 6 soovitab osta, 1 hoida ja 0 müüa.

Praeguse kursiga kaubeldakse Meridian Bioscience aktsiaga 2,02 EUR (2,27 USD) juures.

Meridian Bioscience aktsia (VIVO) on noteeritud 4 börsil, sh: NASDAQ (VIVO), London (0K0K.L), Frankfurt (MR4.F), München (MR4.MU).

Meridian Bioscience Inc is a global company specializing in the development, manufacture, and distribution of diagnostic and testing systems for the rapid and accurate identification of infectious diseases. The company was founded in 1976 and is headquartered in Cincinnati, Ohio. Meridian Bioscience operates several business segments, including diagnostics, OEM, and life science. In the diagnostics segment, the company offers a variety of products for the identification of infectious diseases, including tests for respiratory infections, gastroenteritis, STDs, and Zika virus. Meridian Bioscience's diagnostic products are used in clinical laboratories, hospitals, medical practices, and research laboratories worldwide. The OEM segment of Meridian Bioscience offers customized diagnostic products tailored to the specific requirements of OEM customers. This includes both raw materials and finished products that can be integrated into customers' diagnostic products. The OEM segment of Meridian Bioscience works closely with OEM customers to provide customized, cost-effective, and high-quality products. In the life science segment, Meridian Bioscience offers a wide range of products, including enzymes, antibodies, proteins, buffering solutions, and labeling reagents. These products are used in research and development, diagnostics, and industry. Meridian Bioscience has experienced strong growth in recent years, driven by the introduction of new products, expansion into new markets, and the acquisition of other companies. An example of this is the acquisition of the Bioline Group in 2018, a leading provider of molecular biology products used in research and diagnostics. Meridian Bioscience is committed to developing and manufacturing high-quality products that deliver fast and accurate results. The company works closely with customers and partners to develop innovative products that meet the needs of the healthcare industry. With its wide range of products and commitment to innovation and quality, Meridian Bioscience will continue to play an important role in the diagnostics industry.

Käivet ei saa praegu Meridian Bioscience kohta arvutada.

Kasumit ei saa praegu Meridian Bioscience kohta arvutada.

P/E-suhtarvu ei saa praegu Meridian Bioscience kohta arvutada.

P/S-suhtarvu ei saa praegu Meridian Bioscience kohta arvutada.

Eulpooli kvaliteedinäitaja Meridian Bioscience jaoks on 6/10.

Meridian Bioscience ISIN on US5895841014. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Meridian Bioscience WKN on 871583. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Meridian Bioscience ticker on VIVO. Ticker-sümbol kasutatakse Meridian Bioscience aktsiate kauplemiseks börsil.

Õiglane väärtusTerminal
2,04 USD
Üle-/alahinnangTerminal
Õiglaselt hinnatakse
Tööstus
Tervishoiuvarustus ja tarvikud
Aktsiate arv
Töötajad
Tulu töötaja kohta
504 572,73 USD
Tulukasvu keskmine 5 aastat
EBIT kasvu keskmine 5 aastat
Puhaskasumi kasvu keskmine 5 aastat
Valuuta
USD
Börsi noteerimise algus
29. juuli 1986
ISIN
US5895841014
CUSIP
589584101
SEDOL
2580265
Turukapitalisatsioon
100,74 M USDMicro Cap
52-nädala vahemik
PEG
—
P/E suhe
P/E e 2023
2,70
P/E e 2024
3,84
P/E e 2025
5,36
P/S
P/S e
0,34
EV/EBIT
—
P/B suhe
0,27
ROE (omakapitali tootlus)
ROA (varatootlus)
ROCE (kasutatud kapitali tootlus)
ROIC (investeeritud kapitali tootlus)
10,80 %
Viimati värskendatud 18. okt 2026, 17:25

Meridian Bioscience Börsiticker

FRANKFURT · MR4.FLONDON · 0K0K.LMÜNCHEN · MR4.MUNASDAQ · VIVO

Meridian Bioscience FIGI

MR4:GF · BBG000GT3TJ1MR4:GS · BBG000GT4YY2VIVOUSD:XB · BBG00JSL7CZ9VIVOUSD:XS · BBG00JSL7DF9VIVOGBX:B1 · BBG00L2YZQT9